|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.730 USD | +3.56% |
|
-1.13% | +27.82% |
| 06-18 | TransCode Therapeutics, Inc. - Special Call | |
| 06-03 | TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a | MT |
| Market Cap | 8.01M 7.02M 6.49M 5.97M 11.28M 773M 11.45M 77.49M 30.38M 378M 30.08M 29.42M 1.3B | P/E 2024 |
-0.07x | P/E 2025 | -0.13x |
|---|---|---|---|---|---|
| Enterprise Value | -9.8M -8.59M -7.94M -7.3M -13.81M -945M -14.02M -94.82M -37.17M -462M -36.81M -36M -1.59B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
91.1% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: TransCode Therapeutics, Inc.
| 1 day | +3.56% | ||
| 1 week | -1.13% | ||
| Current month | +40.58% | ||
| 1 month | +85.74% | ||
| 3 months | -0.80% | ||
| 6 months | -2.35% | ||
| Current year | +27.82% |
| 1 week | 8.01 |  | 9.4 |
| 1 month | 4.07 | | 10.69 |
| Current year | 3.82 | | 12.6 |
| 1 year | 3.82 | | 20.99 |
| 3 years | 3.82 | | 118,271.9 |
| 5 years | 3.82 | | 1,000,000 |
| 10 years | 3.82 | | 1,000,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Calais
CEO | Chief Executive Officer | 67 | 2025-10-05 |
Zdravka Medarova
CTO | Chief Tech/Sci/R&D Officer | 52 | 2021-09-30 |
| Chief Executive Officer | 75 | 2024-01-12 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2018-06-30 | |
Philippe Calais
CHM | Chairman | 67 | 2021-02-17 |
Erik Manting
BRD | Director/Board Member | 54 | 2020-12-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/14/24 | Free | Chief Executive Officer | 70,000 | 1.0654% | ||
| 6/14/24 | Free | Chief Financial Officer | 650,000 | 9.8934% | ||
| 6/14/24 | Free | Director | 70,000 | 1.0654% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.56% | -1.13% | -12.17% | -99.99% | 8.01M | |
| +0.21% | -1.34% | +53.17% | +60.65% | 53.83B | |
| +5.37% | +0.75% | +50.39% | +83.03% | 52.1B | |
| -1.20% | -7.43% | +4.35% | +406.96% | 23.48B | |
| +0.74% | +0.73% | -16.23% | -15.55% | 23.13B | |
| +3.46% | +0.79% | +34.01% | -4.47% | 19.36B | |
| -1.18% | -1.15% | +30.12% | -32.02% | 17.56B | |
| -1.67% | -8.56% | +163.95% | +284.69% | 15.2B | |
| +3.62% | -2.42% | +29.70% | +663.64% | 14.83B | |
| -0.70% | -1.72% | +24.87% | +184.19% | 14.06B | |
| Average | +1.22% | -2.65% | +36.21% | +153.11% | 23.36B | |
| Weighted average by Cap. | +1.48% | -2.35% | +41.46% | +140.84% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -16.75M -14.68M -13.58M -12.48M -23.6M -1.62B -23.96M -162M -63.54M -790M -62.91M -61.54M -2.72B | -34.66M -30.37M -28.08M -25.82M -48.81M -3.34B -49.56M -335M -131M -1.63B -130M -127M -5.63B |
| Net Debt | -5.77M -5.06M -4.68M -4.3M -8.13M -557M -8.25M -55.84M -21.89M -272M -21.68M -21.2M -938M | -17.81M -15.61M -14.43M -13.27M -25.09M -1.72B -25.47M -172M -67.56M -840M -66.89M -65.43M -2.89B |
Employees
12
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-20 | US$8.730 | +3.56% | 14,360 |
| 26-07-17 | US$8.430 | +1.93% | 5,860 |
| 26-07-16 | US$8.270 | -4.89% | 6,423 |
| 26-07-15 | US$8.695 | +1.34% | 17,711 |
| 26-07-14 | US$8.580 | +0.23% | 17,232 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- RNAZ Stock
Select your edition
All financial news and data tailored to specific country editions
